Abiopharma

🔍 Horn Howard (Executive)

Company: Ultragenyx Pharmaceutical Inc. (RARE)

Report Date: 2026-04-16

Detailed Transactions and Holdings:

• Acquired 34,674 shares of Common Stock (Direct)
  Date: 2026-04-16 | Code: A | equity_swap_involved: false | shares_owned_after: 115,025.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 59,952 shares of Stock Option (Right to Buy) at $24.52 per share (Derivative)
  Date: 2026-04-16 | Code: A | Expires: 2036-04-16 | equity_swap_involved: false | shares_owned_after: 59,952.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
• F2: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
• F3: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.